Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Sponsor: National Cancer Institute (NCI)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from National Cancer Institute (NCI)
Other Advanced Breast Cancer trials with similar outcome
A PHASE2 clinical study on Advanced Breast Cancer and Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Apr 2017 — Jun 2017 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Rutgers Cancer Institute of New Jersey
- Rutgers, The State University of New Jersey
For direct contact, visit the study record on ClinicalTrials.gov .